Economy

Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump

By Patrick Wingrove

(Reuters) – Eli Lilly (NYSE:LLY) CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump administration.

President-elect Donald Trump met with Ricks and the chief executive of industry lobbying group PhRMA in Florida last week. It was also reported that Pfizer (NYSE:PFE) CEO Albert Bourla attended.

The Lilly CEO did not share details of that conversation during an interview with Carlyle Group (NASDAQ:CG) cofounder David Rubenstein. Nor did he provide more information about the exact reforms he was targeting.

He said the regulatory situation in the U.S. had evolved in a negative way for the pharmaceuticals industry over the last four years.

“My experience having done this for eight years is there’s often more common ground than you think,” said Ricks, who has been CEO of Lilly since 2017.

Ricks said that the Trump administration may raise the policy argument that other developed countries should pay more for drugs, and then prices in the U.S. can be lowered.

Americans pay more for medicines than people in any other country.

Drugmaker executives have previously said they will push to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once Trump is back in office, as well as reform rules governing pharmacy middlemen that negotiate volume-based discounts with drug manufacturers.

Ricks said Lilly had helped bring the cost of some of its insulins down to $35 a month by “compressing what these middlemen get”.

Anti-vaccine activist Robert F. Kennedy Jr., Trump’s pick to lead the United States’ top health agency, was also present at Ricks’ meeting with the president-elect, according to an Axios report last week.

The report said Trump and the company executives discussed how the public and private sectors can collaborate on finding cures for cancer, among other topics.

This post appeared first on investing.com

You May Also Like

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Editor's Pick

Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

Latest News

A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 balanceandcharge.com

Exit mobile version